TSC2 mutation

CI-VAR-00004992Explore in graph →CIViC 4464

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Tuberous Sclerosis1unmapped disease
TSC1 mutation OR TSC2 mutation	Everolimus	Predictive	A	Supports Sensitivity Response	4	submitted	EID11269 In this double-blind, placebo-controlled, phase 3 trial, 117 patients with tuberous sclerosis complex (TSC) and at least one lesion with a diameter of 1 cm or greater, and either serial growth of a su… (full text at CIViC) PMID 23158522 · Franz et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.